市場調查報告書
商品編碼
1380412
2023-2030年全球血管內支架市場Global Intravascular Stents Market 2023-2030 |
預計全球血管內支架市場在預測期(2023-2030年)將以9.4%的CAGR成長。關鍵因素包括週邊血管疾病(PVD)和冠狀動脈疾病(CAD)盛行率的增加。據世界衛生組織 (WHO) 稱,心血管疾病 (CVD) 是全球主要死亡原因,每年估計奪走 1,790 萬人的生命。此外,血管內支架的協議和收購的增加預計將透過促進這些設備的接受和使用的增加來推動市場成長。 2021年12月,健康科技先驅皇家飛利浦簽署協議,收購美國開發微創週邊血管設備的醫療科技公司Vesper Medical Inc.。 Vesper Medical 透過用於治療深部靜脈疾病的先進靜脈支架產品組合進一步擴展了飛利浦的診斷和治療設備產品組合。
全球血管內支架市場按產品、輸送方式和最終用戶進行細分。根據類型,市場分為冠狀動脈支架、神經血管支架、週邊支架、腎動脈支架和主動脈支架。根據輸送方式,市場分為自擴張支架和球囊擴張支架。此外,根據最終用戶,市場細分為醫院、心臟中心和門診手術中心。在最終用戶中,醫院和心臟中心細分市場由於設備齊全、易於使用、高度信任和可靠性,預計將佔據相當大的市場佔有率。
其中,冠狀動脈支架細分市場預計將在全球血管內支架市場中佔據相當大的佔有率。節段性成長歸因於冠心病(CAD)盛行率的增加,當斑塊在動脈中積聚時就會發生冠心病,導致對涉及支架的經皮冠狀動脈介入治療的需求不斷成長。根據國家醫學圖書館的研究,Rao 等人所做的系統性回顧。研究表明,城市地區 CAD 盛行率為 2.5-12.6%,農村地區為 1.4-4.6%。此外,美國食品藥物管理局 (FDA) 批准的產品數量不斷增加也促進了冠狀動脈支架的採用。例如,2022 年 5 月,美國 FDA 批准美敦力公司的藥物洗脫支架 (DES) Onyx Frontier 用於治療 CAD 患者。新的 DES 產品利用與美敦力 Resolute Onyx 相同的平台,旨在改善藥物輸送並提高急性表現。
全球血管內支架市場根據地理位置進一步細分,包括北美(美國和加拿大)、歐洲(英國、義大利、西班牙、德國、法國和歐洲其他地區)、亞太地區(印度、中國、日本) 、韓國和亞洲其他地區)以及世界其他地區(中東和非洲以及拉丁美洲)。其中,由於心血管疾病的盛行率不斷上升以及生活方式的改變,預計亞太地區將在全球市場中佔據顯著佔有率。
在所有地區中,北美地區預計在預測期內將以相當大的CAGR成長。推動北美市場的主要因素是北美地區心血管疾病數量的增加,預計將對未來幾年支架市場的成長產生積極影響。慢性病患者數量的增加預計將推動經皮冠狀動脈介入治療和周邊血管手術的需求。根據美國心臟協會 (AHA) 的數據,心血管疾病仍然是美國的首要死因,2020 年死亡人數為 928,741 人。2020 年,冠心病 (CHD) 是美國的首要死因(41.2%)在美國,CVD 導致的死亡最多,其次是中風(17.3%)、其他CVD (16.8%)、高血壓(12.9%)、心臟衰竭(9.2%) 和動脈疾病(2.6%)。
服務全球血管內支架市場的主要公司包括: Abbott Laboratories、B. Braun SE、Boston Scientific Corp.、Medtronic plc、Terumo Corp.等。市場參與者透過各種策略(包括併購、合作、合作、融資和新產品發布),為市場成長做出了巨大貢獻,以保持市場競爭力。例如,2022 年 11 月,波士頓科學公司收購了 WOLF 血栓切除術 (R) 平台的開發商 Devoro Medical, Inc.,將機械血栓切除術平台添加到週邊干涉產品組合中。創新的非控制台和非溶解的 WOLF 技術使用手指狀尖頭瞄準並快速捕獲血塊,檢索和清除動脈和靜脈系統中的血栓。
Title: Global Intravascular Stents Market Size, Share & Trends Analysis Report by Product (Coronary Stents, Neurovascular Stents, Peripheral Stents, Renal Artery Stents, and Aortic Stents), by Mode of Delivery (Self-Expanding Stents and Balloon-Expandable Stents), by End-User (Hospitals and Cardiac Centers and Ambulatory Surgical Centers),Forecast Period (2023-2030).
The global intravascular stents market is anticipated to grow at a CAGR of 9.4% during the Forecast Period (2023-2030). Pivotal factors including the increasing prevalence of peripheral vascular diseases (PVDs) and coronary artery diseases (CAD). According to the World Health Organization (WHO), cardiovascular diseases (CVDs) are the leading cause of death globally, taking an estimated 17.9 million lives each year. Further, the increasing agreement and acquisition for intravascular stents is projected to drive market growth by promoting increased acceptance and usage of these devices. In December 2021, Royal Philips, a pioneer in health technology signed an agreement to acquire Vesper Medical Inc., a US-based medical technology company that developed minimally invasive peripheral vascular devices. Vesper Medical further expanded Philips' portfolio of diagnostic and therapeutic devices with an advanced venous stent portfolio for the treatment of deep venous disease.
The global intravascular stents market is segmented on the product, mode of delivery and end-user. Based on the type, the market is sub-segmented into coronary stents, neurovascular stents, peripheral stents, renal artery stents and aortic stents. Based on the mode of delivery, the market is sub-segmented into self-expanding stents and balloon-expandable stents. Further, based on end-user, the market is sub-segmented into hospitals and cardiac centers and ambulatory surgical centers. Among the end-user, the hospitals and cardiac centers sub-segment is anticipated to hold a considerable share of the market, owing to the well-equipped settings, easy availability, high trust, and reliability.
Among the product, the coronary stents sub-segment is expected to hold a considerable share of the global intravascular stents market. The segmental growth is attributed to the increasing prevalence of CADs, which occur when plaque accumulates in the arteries, has led to a growing demand for percutaneous coronary intervention treatments involving stents. According to the study of National Library of Medicine, the systematic review done by Rao et al. demonstrated that prevalence of CAD in urban areas was 2.5-12.6% and in rural areas, 1.4-4.6%. Additionally, the rising number of Food and Drug Administration (FDA) approvals of the products are also contributing to the increasing adoption for coronary stents. For instance, in May 2022, the US FDA approved drug-eluting stent (DES) Onyx Frontier, from Medtronic, for the treatment of patients with CAD. The new DES product leverages the same platform as Medtronic's Resolute Onyx, designed to improve the delivery of drugs and improve acute performance.
The global intravascular stents market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America). Among these, Asia-Pacific is anticipated to hold a prominent share of the market across the globe, owing to the increasing prevalence of CVDs, and the and changes in lifestyles.
Among all regions, the North America regions is anticipated to grow at a considerable CAGR over the forecast period. The major factors driving the North America market is the increasing number of cardiovascular disorders across the North America is estimated to positively impact the stents market growth in upcoming years. Increasing patient pool with chronic diseases is expected to drive the demand for percutaneous coronary intervention and peripheral vascular procedures. According to the American Heart Association (AHA), CVDs remains as the leading cause of death in the US, accounted for 928,741 mortalities in the year 2020. In 2020 in the US, coronary heart disease (CHD) was the leading cause (41.2%) of deaths attributable to CVD in the US, followed by stroke (17.3%), other CVD (16.8%), high blood pressure (12.9%), heart failure (9.2%), diseases of the arteries (2.6%).
The major companies serving the global intravascular stents market include: Abbott Laboratories, B. Braun SE, Boston Scientific Corp., Medtronic plc, Terumo Corp., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in November 2022, Boston Scientific Corp., acquired the Devoro Medical, Inc., developer of the WOLF Thrombectomy® Platform, to add mechanical thrombectomy platform to peripheral interventions portfolio. The innovative non-console and lytic-free WOLF technology targets and rapidly captures blood clots using finger-like prongs that retrieve and remove thrombi in the arterial and venous systems.